Questra Clinical Research

Executive Summary

Questra Clinical Research is a Malaysia-based contract research organization (CRO) founded in 2020, specializing in end-to-end clinical trial and bio-analytical services for pharmaceuticals, medical devices, biosimilars, natural products, and advanced therapies such as stem cell and gene therapy. Operating with GCP/GLP-certified teams and a single-roof facility, the company conducts Phase II-IV studies and bioavailability/bioequivalence (BA/BE) studies, emphasizing regulatory compliance, quality, and ethical standards. Headquartered in Penang, Questra serves as a regional partner for sponsors seeking efficient clinical development in Southeast Asia. As a private platform-stage CRO, Questra is well-positioned to capitalize on the growing outsourcing of clinical trials to Asia, driven by cost efficiencies and expanding patient populations. Its expertise in biosimilars and advanced therapies aligns with emerging market trends, and its GCP/GLP certifications provide a competitive edge. The company’s integrated service model and focus on timeliness and data integrity support long-term partnerships. While still early-stage, Questra’s potential to scale and attract multinational clientele underpins its growth outlook, though its private status limits financial visibility.

Upcoming Catalysts (preview)

• Q3 2026Expansion into Phase I clinical trial services60% success
• Q4 2026Strategic partnership with a global pharmaceutical company50% success
• TBDAccreditation from international regulatory authorities (e.g., US FDA or EMA)40% success